Ray Dalio's ABBV Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 14,209 shares of AbbVie Inc. (ABBV) worth $3.25 M, representing 0.01% of the portfolio. First purchased in 2020-Q4, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in ABBV, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 493,340 shares. Largest reduction occurred in Q3 2025, reducing 337,603 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's AbbVie (ABBV) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbbVie (ABBV) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -246,480 | Reduce 94.55% | 14,209 | $228.49 |
| Q3 2025 | -337,603 | Reduce 56.43% | 260,689 | $231.54 |
| Q2 2025 | +493,340 | Add 470.06% | 598,292 | $185.62 |
| Q1 2025 | -181,411 | Reduce 63.35% | 104,952 | $209.52 |
| Q4 2024 | +81,791 | Add 39.98% | 286,363 | $177.70 |
| Q3 2024 | -83,953 | Reduce 29.10% | 204,572 | $197.48 |
| Q2 2024 | -161,254 | Reduce 35.85% | 288,525 | $171.52 |
| Q1 2024 | -157,114 | Reduce 25.89% | 449,779 | $182.10 |
| Q4 2023 | +30,933 | Add 5.37% | 606,893 | $154.97 |
| Q3 2023 | -58,345 | Reduce 9.20% | 575,960 | $149.06 |
| Q2 2023 | +222,875 | Add 54.17% | 634,305 | $134.73 |
| Q1 2023 | +381,328 | Add 1266.79% | 411,430 | $159.37 |
| Q4 2022 | -182,648 | Reduce 85.85% | 30,102 | $161.61 |
| Q3 2022 | +130,900 | Add 159.93% | 212,750 | $134.21 |
| Q2 2022 | +6,334 | Add 8.39% | 81,850 | $153.16 |
| Q1 2022 | +33,661 | Add 80.42% | 75,516 | $162.11 |
| Q4 2021 | -33,241 | Reduce 44.26% | 41,855 | $135.40 |
| Q3 2021 | +22,491 | Add 42.75% | 75,096 | $107.88 |
| Q2 2021 | +52,605 | New Buy | 52,605 | $112.63 |
| Q1 2021 | -25,294 | Sold Out | 0 | $0.00 |
| Q4 2020 | +25,294 | New Buy | 25,294 | $107.14 |
Ray Dalio's AbbVie Investment FAQs
Ray Dalio first purchased AbbVie Inc. (ABBV) in Q4 2020, acquiring 25,294 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held AbbVie Inc. (ABBV) for 21 quarters since Q4 2020.
Ray Dalio's largest addition to AbbVie Inc. (ABBV) was in Q2 2025, adding 598,292 shares worth $111.05 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 14,209 shares of AbbVie Inc. (ABBV), valued at approximately $3.25 M.
As of the Q4 2025 filing, AbbVie Inc. (ABBV) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in AbbVie Inc. (ABBV) was 634,305 shares, as reported at the end of Q2 2023.